Unknown

Dataset Information

0

Efficacy of COVID-19 vaccines in inflammatory bowel disease patients receiving anti-TNF therapy: A systematic review and meta-analysis.


ABSTRACT:

Background and objectives

There are concerns about the serological responses to Coronavirus disease 2019 (COVID-19) vaccines in inflammatory bowel disease (IBD) patients, particularly those receiving anti-TNF therapy. This study aimed to systematically evaluate the efficacy of COVID-19 vaccines in IBD patients receiving anti-TNF therapy.

Methods

Electronic databases were searched to identify relevant studies. We calculated pooled seroconversion rate after COVID-19 vaccination and subgroup analysis for vaccine types and different treatments were performed. Additionally, we estimated pooled rate of T cell response, neutralization response, and breakthrough infections in this population.

Results

32 studies were included in the meta-analysis. IBD patients receiving anti-TNF therapy had relatively high overall seroconversion rate after complete vaccination, with no statistical difference in antibody responses associated with different drug treatments. The pooled positivity rate of T cell response was 0.85 in IBD patients receiving anti-TNF therapy. Compared with healthy controls, the positivity of neutralization assays was significantly lower in IBD patients receiving anti-TNF therapy. The pooled rate of breakthrough infections in IBD patients receiving anti-TNF therapy was 0.04.

Conclusions

COVID-19 vaccines have shown good efficacy in IBD patients receiving anti-TNF therapy. However, IBD patients receiving anti-TNF have a relatively high rate of breakthrough infections and a low level of neutralization response.

SUBMITTER: Dou D 

PROVIDER: S-EPMC10558877 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy of COVID-19 vaccines in inflammatory bowel disease patients receiving <i>anti</i>-TNF therapy: A systematic review and meta-analysis.

Dou Dan D   Zhang Fangyi F   Deng Xin X   Ma Yun Y   Wang Shuqing S   Ji Xingyu X   Zhu Xihan X   Wang Dianpeng D   Zhang Shengsheng S   Zhao Luqing L  

Heliyon 20230905 9


<h4>Background and objectives</h4>There are concerns about the serological responses to Coronavirus disease 2019 (COVID-19) vaccines in inflammatory bowel disease (IBD) patients, particularly those receiving <i>anti</i>-TNF therapy. This study aimed to systematically evaluate the efficacy of COVID-19 vaccines in IBD patients receiving <i>anti</i>-TNF therapy.<h4>Methods</h4>Electronic databases were searched to identify relevant studies. We calculated pooled seroconversion rate after COVID-19 va  ...[more]

Similar Datasets

| S-EPMC10865142 | biostudies-literature
| S-EPMC8921985 | biostudies-literature
| S-EPMC7839545 | biostudies-literature
| S-EPMC4793922 | biostudies-literature
| S-EPMC9928959 | biostudies-literature
| S-EPMC7835139 | biostudies-literature
| S-EPMC5427745 | biostudies-literature
| S-EPMC9171292 | biostudies-literature
| S-EPMC6282128 | biostudies-literature
| 2359035 | ecrin-mdr-crc